ClinicalTrials.gg
RecruitingNCT07170800Updated Jan 30, 2026

A Phase 2b Clinical Study of JDB0131 Benzenesulfonate Tablets

A Phase 2 interventional study of JDB0131 100mg and JDB0131 200mg in Tuberculosis, Multidrug Resistant Pulmonary Tuberculosis and Rifampicin-resistant Tuberculosis, sponsored by WestVac Biopharma Co., Ltd.. Recruiting at 7 sites in China. Open to participants aged 14 Years and older. Per ClinicalTrials.gov, last updated 2026-01-30.

Sponsored by WestVac Biopharma Co., Ltd. · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Feb 2026, 8 months ago, but the record still lists the study as recruiting.
  • Started Sep 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
14 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 62 studies in Tuberculosis with a site in China — 22 open to participants now, 25 under way, 5 of them phase 3. Tuberculosis · China.

Planned enrollment
39th of 47
60 · median 241
Started
2025
with 7 others
Phase 2
10 of 62
4 open now
Primary completion
2026-02
later than 7 of 24 live
Registered
54th of 62
by date

Among the 62 studies in Tuberculosis with a site in China, this one is the 39th largest by planned enrollment of the 47 interventional ones that give a count, is one of 8 that started in 2025, is one of 10 in phase 2, reaches primary completion later than 7 of the 24 other live ones, and was the 54th registered.

Tuberculosis

1,173 studies on the registry are indexed under Tuberculosis; 177 are open to participants now.

Browse Tuberculosis studies →

Open to participants now

22 of the 62 studies in Tuberculosis with a site in China are open now. Recruiting first, the newest first:

16 more — sign in →

All 22 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 112 Tuberculosis studies recruiting now, 65 (58%) set no upper age limit and 37 (33%) stop at 75 or younger; 49 take children under 18; 31 take healthy volunteers.

This study: 14 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 62 studies in Tuberculosis with a site in China, or all of them as a file.
02

Study summary

This is a multicenter, randomized, open-label, active-controlled clinical study designed to evaluate the efficacy, safety, and pharmacokinetic characteristics of different doses of JDB0131 benzenesulfonate tablets compared with delamanid in combination with bedaquiline, linezolid, levofloxacin (moxifloxacin)/clofazimine, etc. in the treatment of patients with drug-resistant (including rifampicin-resistant) tuberculosis for 8 weeks.

03

Conditions studied

  • Tuberculosis
  • Multidrug Resistant Pulmonary Tuberculosis
  • Rifampicin-resistant Tuberculosis

Browse trials for

04

Who can participate

Ages eligible
14 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age: 14 years through 65 years of age, male or female
  • Weight: 40kg ≤ weight ≤ 90kg
  • Patients with clinically confirmed pulmonary tuberculosis, Drug Susceptibility Testing (DST) results confirmed to be at least rifampicin-resistant, molecular or phenotypic DST results within 3 months before enrollment can be received
  • Sputum acid-fast bacilli smear is positive (≥2+ once or 1+ twice at least)
  • Patients who are currently taking anti-tuberculosis treatment or using drugs with anti-tuberculosis effects agree to stop all anti-tuberculosis drug treatment and complete a 7-day
  • Women of reproductive age must agree to use highly effective measures throughout the study and for at least 6 months after discontinuation of the drug. Male participants whose partners are women of reproductive age must agree to use appropriate contraceptive methods throughout the study and for at least 6 months after discontinuation of the drug (see protocol Appendix 1)
  • Fully understand the purpose and requirements of this trial, voluntarily sign the written and agree to abide by the relevant provisions of the informed consent

Exclusion criteria

Exclusion Criteria:

  • Those who cannot take delamanid, bedaquiline, or linezolid for various reasons
  • Take delamanid, bedaquiline, or linezolid for more than 1 month (can be enrolled if evidence of no resistance to the above drugs is provided)
  • Hematogenously disseminated pulmonary tuberculosis or severe extrapulmonary tuberculosis as determined by the investigator; or patients with pulmonary tuberculosis who are assessed by the investigator to be likely to require surgical treatment within 8 weeks
  • History of torsades de pointes or risk factors, including a personal or family history of long syndrome (LQTS), persistent hypothyroidism, or bradycardia
  • Anyone with any of the following cardiovascular diseases or other conditions within 6 months before enrollment:

    1. Myocardial infarction;
    2. Heart surgery or coronary revascularization (coronary artery bypass grafting/percutaneous transluminal coronary angioplasty);
    3. Unstable angina;
    4. Congestive heart failure ( functional class III or IV);
    5. or severe cerebrovascular disease.
  • Peripheral neuropathy grade 3 or 4; Grade 1 or 2 peripheral neuropathy that the investigator judges may progress/worsen during the study; Patients with optic neuritis
  • History of gastrointestinal surgery or resection that may affect the absorption and/or excretion of oral medications
  • Patients who are considered by the investigator to be unsuitable for this trial due to unstable or severe cardiovascular, renal, hepatic, blood, tumor, endocrine metabolic, psychiatric or rheumatic diseases
  • History of alcohol dependence or drug abuse within 6 months before screening, the investigator believes that it may affect the safety of the participants and affect the trial compliance
  • Patients who have used other clinical trial drugs within 3 months before administration
  • Concomitant take drugs that cause bone marrow suppression
  • Concomitant take serotonin reuptake inhibitors, tricyclic antidepressants, serotonin, serotonin receptor agonists, and other drugs
  • Concomitant take drugs that prolong the QT interval, such as quinidine, procainamide, amiodarone, sotalol, etc.
  • Chronic systemic therapy, cumulative take for more than 4 weeks within 3 months before enrollment
  • Allergic to any investigational drug or related substance as confirmed by the researcher's clinical judgment
  • Women who have a positive pregnancy test during screening or are breastfeeding
  • Patients with virus (HBV) positive results (HBsAg, HBeAg, and HBcAb); positive virus (HCV) antibodies and (AST) or alanine aminotransferase (ALT) levels >3 times the ; positive (HIV) antibody test; positive syphilis antibody test and active syphilis
  • Laboratory tests show any of the following:

    1. \< 80 g/L;
    2. \< 75 ✕ 109 /L;
    3. Aspartate aminotransferase (AST) > 3 times the upper limit of normal;
    4. Alanine aminotransferase (ALT) > 3 times the upper limit of normal;
    5. Serum total (TBIL) > 2 times the upper limit of normal;
    6. Serum creatinine (Cr) > 1.5 times the upper limit of normal;
    7. Serum amylase > 2 times the upper limit of normal.
  • The following abnormalities were found in the (ECG):

    1. At least twice QTcF intervals > 450 ms (male) or > 470 ms (female);
    2. Pathological Q waves (defined as >40 ms or deep >0.4-0.5mV);
    3. ECG suggests preexcitation syndrome;
    4. ECG suggests left bundle branch block or right bundle branch block; or second or third degree heart block;
    5. Intraventricular conduction delay with QRS duration >120ms;
    6. Bradycardia with a sinus rate \< 50 bpm.
  • In the investigator's judgment, any condition that affects the subject's compliance with the study protocol, or any serious medical or psychological condition that may affect the interpretation of efficacy and safety data, or any condition that may affect the subject's safety when participating in the trial
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Group A: BJLLfx(M)/C

    Bedaquiline (B) and JDB0131 (J) and Linezolid (L) and Levofloxacin (Lfx) or (Moxifloxacin (M)) / Clofazimine (C) Patients will take medications for 8 consecutive weeks. Patients will be randomized based on fluoroquinolone resistance. If fluoroquinolone-susceptible, patients in group A will receive Levofloxacin (Lfx) or Moxifloxacin (M). If fluoroquinolone-resistant, patients in group A will receive Clofazimine (C).

    Drug: JDB0131 100mg

  • Experimental
    Group B: BJLLfx(M)/C

    Bedaquiline (B) and JDB0131 (J) and Linezolid (L) and Levofloxacin (Lfx) or (Moxifloxacin (M)) / Clofazimine (C). Patients will take medications for 8 consecutive weeks. Patients will be randomized based on fluoroquinolone resistance. If fluoroquinolone-susceptible, patients in group A will receive Levofloxacin (Lfx) or Moxifloxacin (M). If fluoroquinolone-resistant, patients in group A will receive Clofazimine (C).

    Drug: JDB0131 200mg

  • Active comparator
    Group C: BDLLfx/C

    Bedaquiline (B) and Delamanid (D) and Linezolid (L) and Levofloxacin (Lfx) / Clofazimine (C). Patients will take medications for 8 consecutive weeks. Patients will be randomized based on fluoroquinolone resistance. If fluoroquinolone-susceptible, patients in group C will receive Levofloxacin (Lfx). If fluoroquinolone-resistant, patients in group C will receive Clofazimine (C).

    Drug: Delamanid (D)

Interventions

  • DrugJDB0131 100mg

    Bedaquiline (B): For the first 2 weeks, 400 mg qd; then adjust to 200 mg tiw. JDB0131 (J): 100 mg bid. Linezolid (L): 600 mg qd. Levofloxacin (Lfx): According to body weight, patients ≤50 kg, 750 mg qd; patients \>50 kg, 1000 mg qd. Moxifloxacin (M): 400 mg qd. Clofazimine (C): 100 mg qd.

  • DrugJDB0131 200mg

    Bedaquiline (B): For the first 2 weeks, 400 mg qd; then adjust to 200 mg tiw. JDB0131 (J): 200 mg bid. Linezolid (L): 600 mg qd. Levofloxacin (Lfx): According to body weight, patients ≤50 kg, 750 mg qd; patients \>50 kg, 1000 mg qd. Moxifloxacin (M): 400 mg qd. Clofazimine (C): 100 mg qd.

  • DrugOPC-67683Studies of OPC-67683OPC-67683 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Bedaquiline (B): For the first 2 weeks, 400 mg qd; then adjust to 200 mg tiw. Delamanid (D): 100 mg bid. Linezolid (L): 600 mg qd. Levofloxacin (Lfx): According to body weight, patients ≤50 kg, 750 mg qd; patients \>50 kg, 1000 mg qd. Moxifloxacin (M): 400 mg qd. Clofazimine (C): 100 mg qd.

06

What researchers measure

Primary outcomes

  1. Percentage of Patients with Sputum Culture Conversion (SCC)

    SCC was defined as a patient without SCC at baseline who subsequently met the definition of SCC. A patient was classified as having achieved SCC if he/she achieved 2 consecutive sputum cultures negative for growth of mycobacterium tuberculosis (MTB) at least 7 days apart and had no further sputum cultures that were positive for growth within the specified time frame. Patients who have sputum cultures that were positive during treatment but only converted to negative at the end of treatment were also counted as negative.

    Time frame: During the 8-week treatment period and after treatment

Secondary outcomes

  1. Time to Sputum Culture Conversion (SCC)

    SCC was defined as a patient without SCC at baseline who subsequently met the definition of SCC. A patient was classified as having achieved SCC if he/she achieved 2 consecutive sputum cultures negative for growth of mycobacterium tuberculosis (MTB) at least 7 days apart and had no further sputum cultures that were positive for growth within the specified time frame. Patients who have sputum cultures that were positive during treatment but only converted to negative at the end of treatment were also counted as negative. Time to SCC was defined as the earliest time of two consecutive sputum cultures negative for growth, that is, the time (specimen collection time) of the first sputum culture negative for growth among two consecutive sputum cultures negative for growth of mycobacterium tuberculosis (MTB) at least 7 days apart was taken as the negative conversion time, expressed in days.

    Time frame: During the 8-week treatment period and after treatment

  2. Time to positivity (TTP)

    Time-to-positivity (TTP) is defined as the length of time from the beginning of culture incubation to the positive detection of mycobacterium tuberculosis growth.

    Time frame: During the 8-week treatment period and after treatment

  3. Number of Participants With Clinically Significant Abnormality in Vital Signs

    Vital signs included body temperature (degree Celsius), heart rate \[beats/minute (bpm)\], breathe \[times/minute (tpm)\], systolic and diastolic blood pressure \[millimetre of mercury (mm Hg)\].

    Time frame: During the 8-week treatment period

  4. Number of Participants With Clinically Significant Abnormalities in Electrocardiogram (ECG) Values

    The clinically significant abnormal ECG values including ventricular rate outlier, PR outlier, QRS outlier, QT outlier and QTcF outlier.

    Time frame: During the 8-week treatment period

  5. Number of Participants With Clinical Significant Abnormality in Laboratory Test

    Laboratory assessments included parameters for serum chemistry (Aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, lactate dehydrogenase, glutamyl transpeptidase, total bilirubin, direct bilirubin, sodium, potassium, chlorine, urea, creatinine), hematology (Red blood cell count, hemoglobin concentration, mean corpuscular volume, white blood cell count, platelet count, neutrophil count, lymphocyte count, monocyte count, eosinophil count, basophil count), urinalysis (Urine leukocytes, urine red blood cells, urine pH, urine specific gravity, urine protein, urine glucose, urine occult blood), stool routine (stool characteristics, stool color, fecal white blood cells, fecal red blood cells, fecal occult blood test) and other serum chemistry (specified in protocol).

    Time frame: During the 8-week treatment period

  6. Number of Patients With Adverse Events (AEs) and at least one Treatment-emergent Adverse Events (TEAEs)

    An adverse event (AE) is any untoward medical occurrence in a participant/clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with treatment. A TEAE is any new AE or worsening of an existing condition after initiation of study drug.

    Time frame: During the 8-week treatment period

  7. Number of Patients With Serious Adverse Events (SAEs)

    An SAE is an AE that resulted in death, inpatient hospitalization/prolongation of existing hospitalization, persistent or significant disability or incapacity, life-threatening, a congenital anomaly/birth defect, or an important medical event.

    Time frame: During the 8-week treatment period

  8. Number of Participants With Any Concomitant Medication Usage

    Concomitant medications are defined as medications that started on or after the first day of study treatment or were started prior to study treatment but were ongoing on the first day of study treatment.

    Time frame: During the 8-week treatment period

  9. Time to peak (Tmax)

    Time frame: During the 8-week treatment period (specified in protocol)

  10. Peak concentration (Cmax)

    Time frame: During the 8-week treatment period (specified in protocol)

  11. Area under the plasma concentration-time curve from the first medication to 12 hours (AUC0-12)

    Time frame: During the 8-week treatment period (specified in protocol)

  12. Time to peak at steady state (Tss,max)

    Time frame: During the 8-week treatment period (specified in protocol)

  13. Peak concentration at steady state (Css,max)

    Time frame: During the 8-week treatment period (specified in protocol)

  14. Trough concentration at steady state (Css,min)

    Time frame: During the 8-week treatment period (specified in protocol)

  15. Average steady-state plasma concentration (Css,avg)

    Time frame: During the 8-week treatment period (specified in protocol)

  16. Elimination half-life (t1/2,ss)

    Time frame: During the 8-week treatment period (specified in protocol)

  17. Area under the plasma concentration-time curve from the last dose to 12 hours (AUC0-12,ss)

    Time frame: During the 8-week treatment period (specified in protocol)

  18. Area under the plasma concentration-time curve from the last dose to the last measurable concentration time t (AUC0-t,ss)

    Time frame: During the 8-week treatment period (specified in protocol)

  19. Area under the plasma concentration-time curve from the last dose extrapolated to infinity (AUC0-∞,ss)

    Time frame: During the 8-week treatment period (specified in protocol)

  20. Apparent volume of distribution (Vd,ss/F)

    Time frame: During the 8-week treatment period (specified in protocol)

  21. Oral clearance (CLss/F)

    Time frame: During the 8-week treatment period (specified in protocol)

  22. Accumulation ratio: Rac(Cmax) = Cmax,ss on day 56 / Cmax on day 1

    Time frame: During the 8-week treatment period (specified in protocol)

  23. Rac (AUC) = AUC0-12,ss on day 56 / AUC0-12 on day 1

    Time frame: During the 8-week treatment period (specified in protocol)

  24. Fluctuation coefficient: fluctuation percentage at steady state = 100 * (Css,max - Css,min) / Css,avg

    Time frame: During the 8-week treatment period (specified in protocol)

07

Study locations

6 of 7 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Feb 2026, 5 months after the start.

Of 64 phase 2 interventional studies under Tuberculosis, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 36. This study's planned 5 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 3, 2025
First posted
Sep 12, 2025
StartActual
Sep 19, 2025
Primary completionEst.
Feb 28, 2026
CompletionEst.
Sep 4, 2026
Last update
Jan 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07170800
Lead sponsor
WestVac Biopharma Co., Ltd.
Responsible party
Sponsor
First posted
Sep 12, 2025
Start date
Sep 19, 2025
Primary completion
Feb 28, 2026 (estimated)
Completion
Sep 4, 2026 (estimated)
Last update
Jan 30, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion